UNITY Biotechnology Inc Price, Forecast, Insider, Ratings, Fundamentals & Signals

South san francisco, calif., june 29, 2022 (globe newswire) -- unity biotechnology, inc. (“unity”) [nasdaq: ubx], a biotechnology company developing therapeutics to slow, halt, or reverse diseases of aging, today announced that from june 14, 2022, through june 28, 2022, the compensation committee of the board of directors (the “board”) granted a new employee a stock-based award covering an aggregate of 30,000 shares of unity common stock, including options to purchase an aggregate of 30,000 shares of unity common stock. the stock-based award was granted pursuant to the unity 2020 employment inducement incentive plan, as amended, which was approved by the board in march 2020 to provide for grants to newly hired employees as a material inducement for them to commence employment with unity in accordance with nasdaq stock market rule 5635(c)(4).

San francisco, may 26, 2022 (globe newswire) -- unity biotechnology, inc. (“unity”) [nasdaq: ubx], a biotechnology company developing therapeutics to slow, halt, or reverse diseases of aging, today announced that michael samar, current chief financial officer at assembly bio, has been appointed to the company's board of directors as its chair of the audit committee and a member of its compensation committee.

Cellular senescence biology in eye disease was a focal point at arvo opening symposium cellular senescence biology in eye disease was a focal point at arvo opening symposium

12-week safety and efficacy data anticipated by mid-year 2022

South san francisco, calif., march 15, 2022 (globe newswire) -- unity biotechnology, inc. (unity) [nasdaq:ubx], a biotechnology company developing therapeutics to slow, halt, or reverse diseases of aging, today reported financial results for the fourth quarter and full year ended december 31, 2021.

SOUTH SAN FRANCISCO, Calif., July 12, 2022 (GLOBE NEWSWIRE) -- UNITY Biotechnology, Inc. (“UNITY”) [NASDAQ: UBX], a biotechnology company developing therapeutics to slow, halt, or reverse diseases of aging, today announced that 24-week clinical data results from the Phase 1 study of its lead senolytic candidate, UBX1325, in patients with diabetic macular edema and wet age-related macular degeneration will be presented at the American Society of Retina Specialists (ASRS) 40th Annual Scientific Meeting 2022, being held July 13-16, 2022. Details of the presentations are as follows:

Mizuho upgraded Unity Biotechnology Inc (NASDAQ: UBX) to Buy from Neutral with a price target of $7, up from $5 after Unity announced longer-term Phase 1 data for UBX1325 in diabetic macular edema (DME) and wet age-related macular degeneration (AMD). Analyst Salim Syed expects some investor sentiment shift to begin at this point for this "underfollowed" stock.

SOUTH SAN FRANCISCO, Calif., Oct. 06, 2021 (GLOBE NEWSWIRE) -- UNITY Biotechnology, Inc. (“UNITY”) [NASDAQ: UBX], a biotechnology company developing therapeutics to slow, halt, or reverse diseases of aging, today announced that from September 21, 2021, through October 5, 2021, the Compensation Committee of the Board of Directors (the “Board”) granted 4 new employees stock-based awards covering an aggregate of 138,500 shares of UNITY common stock, including options to purchase an aggregate of 138,500 shares of UNITY common stock. The stock-based awards were granted pursuant to the UNITY 2020 Employment Inducement Incentive Plan, as amended, which was approved by the Board in March 2020 to provide for grants to newly hired employees as a material inducement for them to commence employment with UNITY in accordance with Nasdaq Stock Market Rule 5635(c)(4).

Unity Biotechnology Inc (NASDAQ: UBX) announced 12-week data from its ongoing Phase 1 safety study of UBX1325 in diabetic macular edema (DME) and wet age-related macular degeneration (AMD), for whom anti-VEGF therapy was no longer considered beneficial.  The data show strong and sustained responses following a single injection of UBX1325.

16 th Annual Citi BioPharma Conference on September 8-10, 2021

SOUTH SAN FRANCISCO, Calif., Aug. 18, 2021 (GLOBE NEWSWIRE) -- UNITY Biotechnology, Inc. (“UNITY”) [NASDAQ: UBX], a biotechnology company developing therapeutics to slow, halt, or reverse diseases of aging, today announced that from August 3, 2021, through August 17, 2021, the Compensation Committee of the Board of Directors (the “Board”) granted 2 new employees stock-based awards covering an aggregate of 49,000 shares of UNITY common stock, including options to purchase an aggregate of 49,000 shares of UNITY common stock. The stock-based awards were granted pursuant to the UNITY 2020 Employment Inducement Incentive Plan, as amended, which was approved by the Board in March 2020 to provide for grants to newly hired employees as a material inducement for them to commence employment with UNITY in accordance with Nasdaq Stock Market Rule 5635(c)(4).

SOUTH SAN FRANCISCO, Calif., Aug. 16, 2021 (GLOBE NEWSWIRE) -- UNITY Biotechnology, Inc. (UNITY) [NASDAQ:UBX], a biotechnology company developing therapeutics to slow, halt, or reverse diseases of aging, today announced that members of its senior management team will present at the upcoming H.C. Wainwright Ophthalmology Virtual Conference.

UBX1325 demonstrates favorable tolerability in Phase 1 safety study and improvement in visual acuity and central subfield thickness in majority of patients with diabetic macular edema (DME) and wet age-related macular degeneration (AMD)

SUZHOU, China, and ROCKVILLE, Md., July 28, 2021 /PRNewswire/ -- Ascentage Pharma (6855.HK), a global biopharmaceutical company engaged in developing novel therapies for cancers, chronic hepatitis B (CHB), and age-related diseases, today announced that its global licensee, UNITY Biotechnology, Inc. ("UNITY", NASDAQ:UBX), has reported encouraging data from a Phase I clinical study of UBX1325, an investigational Bcl-xL inhibiting compound, in patients with certain advanced vascular eye diseases, and has already dosed the first patient in the subsequent Phase IIa clinical study.

I recently covered Unity's transition away from its failed osteoarthritis program to its ophthalmology program focused on retinal diseases.